Maike Sauer

Koeln, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

DNA damage response and evasion from immunosurveillance in CLL: new options for NK cell-based immunotherapies.

DNA damage response and evasion from immunosurveillance in CLL: new options for NK cell-based immunotherapies.

Journal: Frontiers in genetics

Published: December 01, 2014

The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines.

The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines.

Journal: PloS one

Published: June 13, 2013

Regulation of self-ligands for activating natural killer cell receptors.

Regulation of self-ligands for activating natural killer cell receptors.

Journal: Annals of medicine

Published: May 25, 2013

Induction of the DNA damage response by IAP inhibition triggers natural immunity via upregulation of NKG2D ligands in Hodgkin lymphoma in vitro.

Induction of the DNA damage response by IAP inhibition triggers natural immunity via upregulation of NKG2D ligands in Hodgkin lymphoma in vitro.

Journal: Biological chemistry

Published: April 19, 2013

Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity.

Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity.

Journal: Blood

Published: March 20, 2013

Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients.

Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: March 06, 2013

The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma.

The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma.

Journal: International journal of cancer

Published: January 29, 2013

Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma.

Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma.

Journal: American journal of hematology

Published: September 05, 2012

Showing 1-8 of 8

Last Updated: 09/26/2026